Home Cart Sign in  
Chemical Structure| 1644069-80-6 Chemical Structure| 1644069-80-6

Structure of DDR Inhibitor
CAS No.: 1644069-80-6

Chemical Structure| 1644069-80-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

DDR Inhibitor is a potent discoidin domain receptor (DDR) inhibitor, with an IC50 of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of DDR Inhibitor

CAS No. :1644069-80-6
Formula : C23H20FN5O2
M.W : 417.44
SMILES Code : O=C(C1=CN=C2C=CC=CN21)NC3=CC(CNC(NC4=CC=CC(F)=C4)=O)=CC=C3C
MDL No. :MFCD31567545

Safety of DDR Inhibitor

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of DDR Inhibitor

RTK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02516111 Chronic Periodontitis Phase 2 Phase 3 Completed - -
NCT02600520 Chronic Periodontitis Phase 2 Phase 3 Completed - -
NCT03404960 Pancreatic Adenocarcinoma Phase 1 Phase 2 Recruiting June 2021 United States, Pennsylvania ... More >> University of Pennsylvania, Abramson Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Danielle Karlson    215-220-9704    danielle.Karlson@uphs.upenn.edu    Principal Investigator: Kim Reiss Binder, MD Less <<
NCT03609216 Infiltrating Bladder Urothelia... More >>l Carcinoma Stage II Bladder Urothelial Carcinoma Stage III Bladder Urothelial Carcinoma Less << Phase 2 Recruiting February 2029 -
NCT03448718 Metastatic Urothelial Cancer Phase 2 Recruiting March 2023 United States, Illinois ... More >> University of Chicago Medical Center Recruiting Chicago, Illinois, United States, 60637 Contact: Glenna Smith Conley    773-834-2143    gsmith6@bsd.uchicago.edu    Principal Investigator: Peter O'Donnell, MD          United States, New York Icahn School of Medicine at Mount Sinai Recruiting New York, New York, United States, 10029-6542 Contact: Matthew Galsky    212-824-5452    matthew.galsky@mssm.edu    United States, Utah Huntsman Cancer Institute University of Utah Recruiting Salt Lake City, Utah, United States, 84112-5550 Contact: Sumati Gupta, MD       sumati.gupta@hci.utah.edu    Principal Investigator: Sumati Gupta, MD Less <<
NCT03395197 mCRPC Phase 3 Recruiting November 2024 United States, Alaska ... More >> Alaska Urological Institute dba Alaska Clinical Research Center Not yet recruiting Anchorage, Alaska, United States, 99503 United States, Arizona Urological Associates of Southern Arizona, PC Recruiting Tucson, Arizona, United States, 85715 Urological Associates of Southern Arizona, P.C. Recruiting Tucson, Arizona, United States, 85741 United States, California Marin Cancer Care, Inc. Not yet recruiting Greenbrae, California, United States, 94904 San Diego Clinical Trials Not yet recruiting San Diego, California, United States, 92120 United States, Colorado The Urology Center of Colorado Recruiting Denver, Colorado, United States, 80211 United States, Nebraska GU Research Network/Urology Cancer Center Recruiting Omaha, Nebraska, United States, 68130 United States, New Jersey New Jersey Urology, LLC Not yet recruiting Voorhees, New Jersey, United States, 08043 United States, New York Premier Medical Group of the Hudson Valley PC Not yet recruiting Poughkeepsie, New York, United States, 12601 Associated Medical Professionals of New York, PLLC Not yet recruiting Syracuse, New York, United States, 13210 United States, Ohio TriState urologic Services PSC Inc., dba The Urology Group Not yet recruiting Cincinnati, Ohio, United States, 45212 United States, South Carolina Carolina Urologic Research Center Recruiting Myrtle Beach, South Carolina, United States, 29572 United States, Tennessee Urology Associates P.C. Not yet recruiting Nashville, Tennessee, United States, 37209 United States, Utah University of Utah, Huntsman Cancer Hospital Recruiting Salt Lake City, Utah, United States, 84112 University of Utah, Huntsman Cancer Institute Recruiting Salt Lake City, Utah, United States, 84112 Less <<
NCT01491633 Squamous Cell Lung Cancer Phase 2 Terminated(Safety issues/conce... More >>rns per DF/HCC PI) Less << - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less <<
NCT01491633 - Terminated(Safety issues/conce... More >>rns per DF/HCC PI) Less << - -
NCT02067416 Breast Cancer Phase 2 Terminated(Funding agent withd... More >>rew funding) Less << - United States, Texas ... More >> Houston Methodist Hospital Houston, Texas, United States, 77030 Less <<
NCT01514864 Carcinoma, Non-small Cell Lung Phase 2 Terminated(Lack of efficacy an... More >>d slow accrual) Less << - United States, Florida ... More >> H. Lee Moffitt Cancer & Research Institute Tampa, Florida, United States, 33612 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Brazil Local Institution Barretos, Sao Paulo, Brazil, 14784 Local Institution S?o Paulo, Sao Paulo, Brazil, 05403 Canada, Ontario The Ottawa Hospital Cancer Centre Ottawa, Ontario, Canada, K1H 8L6 Germany Local Institution Frankfurt, Germany, 60488 Local Institution Heidelberg, Germany, 69120 Local Institution Heidelberg, Germany, 69126 Local Institution Koeln, Germany, 50924 Local Institution Koeln, Germany, 50931 Poland Local Institution Gdansk, Poland, 80-219 Local Institution Lodz, Poland, 93-509 Local Institution Warsaw, Poland, 02-781 Taiwan Local Institution Taipei, Taiwan, 112 United Kingdom Local Institution Cambridge, Cambridgeshire, United Kingdom, CB2 2QQ Local Institution London, Greater London, United Kingdom, SW3 6JJ Local Institution Manchester, Greater Manchester, United Kingdom, M20 4BX Local Institution Edinburgh, Midlothian, United Kingdom, EH4 2XU Local Institution Sutton, Surrey, United Kingdom, SM2 5PT Local Institution Gwent, United Kingdom, NP20 2UB Less <<
NCT01625286 Advanced or Metastatic Breast ... More >>Cancer ER+ve Advanced or Metastatic Breast Cancer Less << Phase 1 Phase 2 Active, not recruiting March 29, 2019 -
NCT02465060 Advanced Malignant Solid Neopl... More >>asm Bladder Carcinoma Breast Carcinoma Cervical Carcinoma Colon Carcinoma Colorectal Carcinoma Endometrial Carcinoma Esophageal Carcinoma Gastric Carcinoma Glioma Head and Neck Carcinoma Kidney Carcinoma Liver and Intrahepatic Bile Duct Carcinoma Lung Carcinoma Lymphoma Malignant Uterine Neoplasm Melanoma Ovarian Carcinoma Pancreatic Carcinoma Plasma Cell Myeloma Prostate Carcinoma Rectal Carcinoma Recurrent Bladder Carcinoma Recurrent Breast Carcinoma Recurrent Cervical Carcinoma Recurrent Colon Carcinoma Recurrent Colorectal Carcinoma Recurrent Esophageal Carcinoma Recurrent Gastric Carcinoma Recurrent Glioma Recurrent Head and Neck Carcinoma Recurrent Liver Carcinoma Recurrent Lung Carcinoma Recurrent Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Melanoma Recurrent Ovarian Carcinoma Recurrent Pancreatic Carcinoma Recurrent Plasma Cell Myeloma Recurrent Prostate Carcinoma Recurrent Rectal Carcinoma Recurrent Skin Carcinoma Recurrent Thyroid Gland Carcinoma Recurrent Uterine Corpus Carcinoma Refractory Lymphoma Refractory Malignant Solid Neoplasm Refractory Plasma Cell Myeloma Skin Carcinoma Thyroid Gland Carcinoma Uterine Corpus Cancer Less << Phase 2 Recruiting - -
NCT03037606 Gastroesophageal Reflux Diseas... More >>e Less << Phase 4 Completed - Turkey ... More >> Ege University Facult of Medicine Gastroenterology Department Izmir, Turkey, 35100 Less <<
NCT03330405 Avelumab in Combination With T... More >>alazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors Less << Phase 2 Recruiting March 28, 2020 -
NCT03022409 Head and Neck Squamous Cell Ca... More >>rcinoma Less << Phase 1 Recruiting September 3, 2019 United States, Pennsylvania ... More >> Research Site Recruiting Pittsburgh, Pennsylvania, United States, 15240 Research Site Not yet recruiting Pittsburgh, Pennsylvania, United States, 15240 France Research Site Not yet recruiting Toulouse cedex 9, France, 31052 Research Site Not yet recruiting Villejuif, France, 94805 Taiwan Research Site Not yet recruiting Taipei, Taiwan, 100 United Kingdom Research Site Not yet recruiting Birmingham, United Kingdom, B15 2TT Research Site Not yet recruiting Manchester, United Kingdom, M20 4BX Less <<
NCT03740893 Breast Neoplasm Phase 2 Not yet recruiting August 2023 United Kingdom ... More >> Royal Bournemouth Hospital Not yet recruiting Bournemouth, Dorset, United Kingdom, BH7 7DW Bristol Haematology and Oncology Centre Not yet recruiting Bristol, England, United Kingdom, BS2 8ED King's College Hospital London, England, United Kingdom, SE5 9RS Christie Hospital NHS Trust Not yet recruiting Manchester, England, United Kingdom, M20 4BX Belfast City Hospital Not yet recruiting Belfast, Northern Ireland, United Kingdom, BT9 7AB Velindre Cancer Center at Velinde Hospital Not yet recruiting Cardiff, Wales, United Kingdom, CF14 2TL Queen Elizabeth Hospital, University Hospitals Birmingham NHS Trust Not yet recruiting Birmingham, United Kingdom Guy's and St Thomas' Hospital NHS Foundation Trust Not yet recruiting London, United Kingdom, SE1 9RT Weston Park Hospital Not yet recruiting Sheffield, United Kingdom Less <<
NCT01514864 - Terminated(Lack of efficacy an... More >>d slow accrual) Less << - -
NCT03207347 Mesothelioma ... More >>Uveal Melanoma Renal Cell Carcinoma Cholangiocarcinoma Less << Phase 2 Recruiting December 2022 United States, Florida ... More >> University of Florida Recruiting Gainesville, Florida, United States, 32610 Principal Investigator: Thomas George, MD, FACP Less <<
NCT02219711 Advanced Cancer Phase 1 Recruiting March 2019 -
NCT03678883 Cancer Lympho... More >>ma Pancreatic Cancer Glioblastoma Multiforme Sarcoma Breast Cancer Bladder Cancer Renal Cancer Ovarian Cancer Refractory Cancer Refractory Neoplasm Refractory Non-Hodgkin Lymphoma Refractory Brain Tumor Pancreatic Adenocarcinoma Resistant Cancer Neoplasm Metastasis Neoplasm of Bone Neoplasm, Breast Neoplasm of Lung Neoplasms,Colorectal Neoplasms Pancreatic Malignant Glioma Malignancies Malignancies Multiple Bone Metastases Bone Neoplasm Bone Cancer Pancreas Cancer Pancreatic Neoplasms Breast Neoplasms Less << Phase 1 Phase 2 Recruiting November 2022 United States, Rhode Island ... More >> Rhode Island Hospital Recruiting Providence, Rhode Island, United States, 02903 Contact: Benedito Carneiro, MD       Benedito.Carneiro@Lifespan.org Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

11.98mL

2.40mL

1.20mL

23.96mL

4.79mL

2.40mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories